Open AccessAntimicrobial peptides and the gut microbiome in inflammatory bowel disease
Author(s) -
John Gubatan,
Derek Holman,
Christopher J Puntasecca,
Danielle Polevoi,
Samuel J. Rubin,
Stephan Rogalla
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i43.7402
Subject(s) - pathogenesis , microbiome , inflammatory bowel disease , antimicrobial peptides , gastrointestinal tract , immune system , immunology , gut flora , disease , biology , barrier function , antimicrobial , medicine , microbiology and biotechnology , bioinformatics
Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD.